StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note published ...

In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $73.4, a ...

Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential ...

A recent study provided key insights into brain degeneration in DLB, which may help clinicians better monitor this ...

The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh is one of the country’s hubs for researchers ...

POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce its ...

A study by the Medical University of Vienna demonstrated that augmented reality (AR) in pediatric epilepsy surgery enhances ...

A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with ...